GeneNews announces 2007 year end results (loss for the quarter ended December 31 2...)

GeneNews announces 2007 year end results

Date:3/26/2008

loss for the quarter ended December 31, 2007 was $2.6 million or ($0.05) per common share compared with a net loss of $2.7 million or ($0.05) per common share for the same period last year. The net loss is reflective of the Company's continuing focus on research and development and the process leading to commercialization of its first product ColonSentry(TM), a convenient and patient-friendly blood-based test that can assess a patient's current risk for colon cancer, and the advancement of related products in the Company's pipeline.

Financial results (CDN dollars) for the year-ended December 31, 2007:

Total revenue for the year-ended December 31, 2007 was $2.2 million compared with $3.3 million for the same period last year. Of the revenues in 2007, $0.2 resulted from the prostate disease biomarker development agreement and $1.7 representing the final revenue from a collaboration agreement with Pfizer. In 2006, revenues resulted entirely from the Pfizer agreement.

Interest earned during the year-end ended December 31, 2007 was $822,000, compared to $448,000 for the corresponding period during the prior year.

Total operating expenditures for the year-ended December 31, 2007 were $12.6 million compared with $12.7 million for the same period last year. Research and development expenses for the quarter were $8.9 million compared with $9.5 million for the same period last year. General and administrative expenses for the year-ended December 31, 2007 were $2.7 million compared with $1.9 million for the corresponding period in 2006.

The net loss for the year-ended December 31, 2007 was $9.6 million or ($0.17) per common share compared to a net loss of $8.9 million or ($0.18) per common share for the same period last year. The Company's continuing focus is on research and development leading to commercialization of its first product and the development of related products in the Company's pipeline.

As at December 31, 2007, the Compa
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results

Post Your Comments:

GeneNews announces 2007 year end results(loss for the quarter ended December 31 2...)